235 related articles for article (PubMed ID: 33977908)
1. Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.
Riccardi N; Saderi L; Borroni E; Tagliani E; Cirillo DM; Marchese V; Matteelli A; Piana A; Castellotti P; Ferrarese M; Gualano G; Palmieri F; Girardi E; Codecasa L; Sotgiu G
Int J Tuberc Lung Dis; 2021 May; 25(5):395-399. PubMed ID: 33977908
[No Abstract] [Full Text] [Related]
2. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
Riccardi N; Alagna R; Saderi L; Ferrarese M; Castellotti P; Mazzola E; De Lorenzo S; Viggiani P; Udwadia Z; Besozzi G; Cirillo D; Sotgiu G; Codecasa L;
BMC Infect Dis; 2019 Jun; 19(1):564. PubMed ID: 31253115
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and treatment outcome of MDR and pre-XDR TB in international migrants at two reference centers in the North of Italy: a cross-sectional study coordinated by Stop TB Italia Onlus.
Riccardi N; Pontarelli A; Alagna R; Saderi L; Ferrarese M; Castellotti P; Viggiani P; Cirillo D; Besozzi G; Sotgiu G; Codecasa L;
Public Health; 2020 Mar; 180():17-21. PubMed ID: 31837610
[TBL] [Abstract][Full Text] [Related]
5. Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
Kherabi Y; Fréchet-Jachym M; Rioux C; Yazdanpanah Y; Méchaï F; Pourcher V; Robert J; Guglielmetti L;
Emerg Infect Dis; 2022 Sep; 28(9):1796-1804. PubMed ID: 35997386
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Diriba G; Alemu A; Yenew B; Tola HH; Gamtesa DF; Mollalign H; Eshetu K; Moga S; Abdella S; Tollera G; Kebede A; Dangisso MH
Int J Infect Dis; 2023 Jul; 132():50-63. PubMed ID: 37072053
[TBL] [Abstract][Full Text] [Related]
7. Multidrug- and extensively drug-resistant tuberculosis, Germany.
Eker B; Ortmann J; Migliori GB; Sotgiu G; Muetterlein R; Centis R; Hoffmann H; Kirsten D; Schaberg T; Ruesch-Gerdes S; Lange C;
Emerg Infect Dis; 2008 Nov; 14(11):1700-6. PubMed ID: 18976552
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Tiberi S; Payen MC; Sotgiu G; D'Ambrosio L; Alarcon Guizado V; Alffenaar JW; Abdo Arbex M; Caminero JA; Centis R; De Lorenzo S; Gaga M; Gualano G; Roby Arias AJ; Scardigli A; Skrahina A; Solovic I; Sulis G; Tadolini M; Akkerman OW; Alarcon Arrascue E; Aleska A; Avchinko V; Bonini EH; Chong Marín FA; Collahuazo López L; de Vries G; Dore S; Kunst H; Matteelli A; Moschos C; Palmieri F; Papavasileiou A; Spanevello A; Vargas Vasquez D; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2016 Apr; 47(4):1235-43. PubMed ID: 26965290
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of pre- and extensively drug-resistant tuberculosis in Johannesburg, South Africa.
Nkurunziza J; Karstaedt AS; Louw R; Padanilam X
Int J Tuberc Lung Dis; 2018 Dec; 22(12):1469-1474. PubMed ID: 30606319
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study.
Sharma SK; George N; Kadhiravan T; Saha PK; Mishra HK; Hanif M
Indian J Med Res; 2009 Oct; 130(4):392-5. PubMed ID: 19942741
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.
Liu CH; Li L; Chen Z; Wang Q; Hu YL; Zhu B; Woo PC
PLoS One; 2011 Apr; 6(4):e19399. PubMed ID: 21559362
[TBL] [Abstract][Full Text] [Related]
13. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting.
Vella V; Racalbuto V; Guerra R; Marra C; Moll A; Mhlanga Z; Maluleke M; Mhlope H; Margot B; Friedland G; Shah NS; Gandhi NR
Int J Tuberc Lung Dis; 2011 Sep; 15(9):1170-5, i. PubMed ID: 21943840
[TBL] [Abstract][Full Text] [Related]
14. From multidrug- to extensively drug-resistant tuberculosis: upward trends as seen from a 15-year nationwide study.
Stoffels K; Allix-Béguec C; Groenen G; Wanlin M; Berkvens D; Mathys V; Supply P; Fauville-Dufaux M
PLoS One; 2013; 8(5):e63128. PubMed ID: 23671662
[TBL] [Abstract][Full Text] [Related]
15. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
Chang KC; Yew WW
Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China.
He XC; Tao NN; Liu Y; Zhang XX; Li HC
BMC Infect Dis; 2017 Aug; 17(1):555. PubMed ID: 28793873
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
18. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP
JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis.
Shah I; Antony S; Jaiswal A; Bodhanwala M; Shah D; Tipre P; Salve J; Parmar M; Sachdeva KS
Pediatr Infect Dis J; 2022 May; 41(5):401-404. PubMed ID: 35153288
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.
De Lorenzo S; Alffenaar JW; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Bolhuis MS; van Altena R; Viggiani P; Piana A; Spanevello A; Migliori GB
Eur Respir J; 2013 Jun; 41(6):1386-92. PubMed ID: 22997218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
